MedTrace Logo

Vasoactive-inotropic Support and Levosimendan Use After Lung Transplantation

NCT05702333 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-04-05

No results posted yet for this study

Summary

Bilateral Lung transplantation (LUTX) is performed in selected patients with end-stage respiratory failure. During surgery, pulmonary arteries are sequentially cross-clamped. This can cause acute heart failure and hemodynamic instability that eventually persist into the postoperative period, leading to the need for prolonged vasoactive support in the postoperative Intensive Care Unit. Levosimendan is a relatively new vasoactive-inotropic drug, with different pharmacodynamic properties.

This observational retrospective cohort study primarily aims 1) to describe the need for prolonged vasoactive support; 2) to evaluate the risk factors for prolonged vasoactive support; 3) to assess the impact of prolonged vasoactive support on outcomes. The secondary aim is to describe the use of Levosimendan in this cohort of patients.

Conditions

  • Lung Transplant; Complications

Interventions

DRUG

Epinephrine Norepinephrine Dobutamine Dopamine Levosimendan

Vasoactive-inotropic drugs were administered according to clinical decision of the doctor in charge.

Sponsors & Collaborators

  • Policlinico Hospital

    lead OTHER

Principal Investigators

  • Vittorio Scaravilli, MD · University of Milan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2022-07-31
Completion
2022-07-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05702333 on ClinicalTrials.gov